News Articles Tagged: ESR1 Mutation Therapy

Elacestrant Intermediate: The Foundation for Next-Generation Breast Cancer Treatment

Explore the significance of 6-(2-amino-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol as an Elacestrant intermediate and its impact on advanced breast cancer treatment, supported by NINGBO INNO PHARMCHEM CO.,LTD.

Advancing Cancer Treatment: The Significance of ESR1 Mutations and Targeted Therapies

Explore how understanding ESR1 mutations in breast cancer has led to the development of targeted therapies like Elacestrant, supported by intermediates from NINGBO INNO PHARMCHEM.